Literature DB >> 19333223

Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.

Francesco Bertoldo1, Giuseppe Tonini, Bruno Vincenzi, Daniele Santini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19333223     DOI： 10.1038/nrclinonc.2009.24

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Authors:  Susan L Greenspan; Ronald D Emkey; Henry G Bone; Stuart R Weiss; Norman H Bell; Robert W Downs; Clark McKeever; Sam S Miller; Michael Davidson; Michael A Bolognese; Anthony L Mulloy; Norman Heyden; Mei Wu; Amarjot Kaur; Antonio Lombardi
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

Review 2.  Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen?

Authors:  Hongliu Ding; Terry S Field
Journal:  Cancer Treat Rev       Date:  2007-06-15       Impact factor: 12.111

Review 3.  Cancer treatment-induced bone loss in breast and prostate cancer.

Authors:  Fred Saad; Jonathan D Adachi; Jacques P Brown; Leah A Canning; Karen A Gelmon; Robert G Josse; Kathleen I Pritchard
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 4.  Bone quality: the material and structural basis of bone strength.

Authors:  Ego Seeman
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

5.  Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.

Authors:  Adam Brufsky; Nigel Bundred; Robert Coleman; Rosemary Lambert-Falls; Raul Mena; Peyman Hadji; Lixian Jin; Nora Schenk; Solveig Ericson; Edith A Perez
Journal:  Oncologist       Date:  2008-05

6.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.

Authors:  Michael Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Franz Kainberger; Helmut Kässmann; Jutta Claudia Piswanger-Sölkner; Michael Seifert; Ferdinand Ploner; Christian Menzel; Peter Dubsky; Florian Fitzal; Vesna Bjelic-Radisic; Günther Steger; Richard Greil; Christian Marth; Ernst Kubista; Hellmut Samonigg; Peter Wohlmuth; Martina Mittlböck; Raimund Jakesz
Journal:  Lancet Oncol       Date:  2008-08-19       Impact factor: 41.316
  6 in total
  3 in total

1.  Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.

Authors:  Shiv K Singh; Sandra Baumgart; Garima Singh; Alexander O König; Kristina Reutlinger; Lorenz C Hofbauer; Peter Barth; Thomas M Gress; Gwen Lomberk; Raul Urrutia; Martin E Fernandez-Zapico; Volker Ellenrieder
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

Review 2.  Antiresorptive therapy in the management of cancer treatment-induced bone loss.

Authors:  Ashwani Garg; Kim Leitzel; Suhail Ali; Allan Lipton
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

3.  Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.

Authors:  Allan Lipton; Matthew R Smith; Georgiana K Ellis; Carsten Goessl
Journal:  Clin Med Insights Oncol       Date:  2012-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.